Rising Rates May Hurt Small-Cap Biotech ETF Valuations

MarketsETF Trends

The Federal Reserve has hiked interest rates for the second time in a decade and plans to raise rates three more times next year. With higher interest rates, investors may find small-cap biotechnology exchange traded funds that track companies banking on a breakthrough drug less appealing. While few development-stage companies fund their operations with debt…Click to read more at ETFtrends.com.

Continue Reading Below